Royalty Pharma forward PE RPRX

Share price divided by analysts' consensus earnings for the next twelve months, since 2020.

Today, Oct 23, 2026: 12.9×
6-year median: 9.3×
Against its 6-year history: 76th; percentile: 0 is its lowest day, 100 its highest
6-year range: 6.2× to 19.4×
Peer median: 25.0×

Royalty Pharma's forward PE is 12.9× as of Oct 23, 2026.

That is above its 6-year median of 9.3×, higher than on 76% of days in the last 6 years.

Over that time it ranged from 6.2× in Dec 2024 to 19.4× in Jun 2020.

The median for 10 healthcare stocks of a similar size is 25.0×.

Forward PE over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	12.9×	7.8×	12.9×
2025	7.9×	6.4×	8.2×
2024	6.3×	6.2×	7.9×
2023	7.2×	6.8×	9.7×
2022	9.1×	9.1×	13.4×
2021	13.3×	11.9×	18.8×
2020	18.1×	14.3×	19.4×

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

Company	Forward PE
RPRXRoyalty Pharma	12.9×
RMDResMed	20.8×
BIIBBiogen	19.1×
CNCCentene	15.0×
ZTSZoetis	13.1×
MTDMettler-Toledo International	33.9×
ILMNIllumina	47.2×
GEHCGE HealthCare Technologies	13.8×
ONCBeOne Medicines	48.1×
IDXXIDEXX Laboratories	35.9×
WATWaters	29.2×
Peer median	25.0×

Where Royalty Pharma ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.